AC
NVIV

Armistice Capital’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Armistice Capital’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-222,000
Closed -$522K – 274
2022
Q4 		$522K Buy
+222,000
New +$557K 0.01% 141

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Armistice Capital's NVIV Position: Q1 2023 in Review

Armistice Capital sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2023, closing a stake of 222,000 shares — an estimated $522K sold.

Armistice Capital first reported a position in NVIV in Q4 2022 and held it in 1 quarter. The position peaked at $522K in Q4 2022. 20 funds tracked by Wall St. Rank hold NVIV as of Q1 2023.

  • Armistice Capital reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2023 after selling out during the quarter.
  • Armistice Capital sold 222,000 InVivo Therapeutics Holdings Corp shares in Q1 2023, an estimated $522K.
  • Armistice Capital first reported a position in InVivo Therapeutics Holdings Corp in Q4 2022 and held it in 1 quarter.
  • Armistice Capital's InVivo Therapeutics Holdings Corp position peaked at $522K in Q4 2022.
  • 20 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.